95656-88-5

Usage

Uses

Used in Organic Synthesis:
3-HYDROXY-1-N-CBZ-PYRROLIDINE is used as a reagent in organic synthesis for its ability to contribute to the formation of complex organic molecules. Its unique structure and functional groups make it a valuable component in creating a wide range of chemical products.
Used in Pharmaceutical Production:
In the pharmaceutical industry, 3-HYDROXY-1-N-CBZ-PYRROLIDINE is used as an intermediate for the production of various pharmaceuticals. Its role in the synthesis of drugs is significant, as it can be incorporated into the molecular structures of medications, potentially enhancing their efficacy and properties.
Used in Agrochemical Production:
3-HYDROXY-1-N-CBZ-PYRROLIDINE also finds application in the agrochemical sector, where it serves as an intermediate in the synthesis of various agrochemicals. Its use in this industry is crucial for developing effective products for agricultural applications, such as pesticides and herbicides, which can improve crop yields and protect plants from pests.

InChI:InChI=1/C12H15NO3/c14-11-6-7-13(8-11)12(15)16-9-10-4-2-1-3-5-10/h1-5,11,14H,6-9H2

Upstream product

• 40499-83-0 pyrrolidin-3-ol 
• 620-73-5 phenyl chloroacetate 
• 31970-04-4 1-carboxybenzyl-3-pyrrolidine 
• 91958-67-7 (R)-4-hydroxy-1-(benzyloxycarbonyl)pyrrolidine-2-carboxylic acid 
• 501-53-1 benzyl chloroformate 
• 197891-66-0 4-benzyloxycarbamate-butyraldehyde diethyl acetal 
• 1885-14-9 phenyl chloroformate 
• 104706-47-0 (R)-3-hydroxypyrrolidine hydrochloride 
• 111810-68-5 3-hydroxypyrrolidine hydrochloride 
• 31139-36-3 dibenzyl dicarbonate 
• 130312-02-6 benzyl 3-oxopyrrolidine-1-carboxylate 
• 98-88-4 benzoyl chloride 

Downstream Products

• 130312-02-6 benzyl 3-oxopyrrolidine-1-carboxylate 
• 174621-88-6 (S)-3-(acetyloxy)-1-pyrrolidinecarboxylic acid, phenylmethyl ester 
• 100858-32-0 (S)-3-hydroxy-1-pyrrolidinecarboxylic acid phenylmethyl ester 
• 139524-57-5 N-(benzyloxycarbonyl)-7-aza-1,4-dioxospiro<4.4>nonane 
• 100858-33-1 (3R)-3-hydroxy-pyrrolidine-1-carboxylic acid benzyl ester 
• 130403-93-9 (S)-benzyl 3-acetoxypyrrolidine-1-carboxylate 
• 188846-98-2 benzyl 3-[[(4-methylphenyl)sulfonyl]oxy]-1-pyrrolidine carboxylate 
• 947499-08-3 benzyl 3-(tetrahydro-2H-pyran-2-yloxy)pyrrolidine-1-carboxylate 
• 169750-16-7 benzyl 3-fluoropyrrolidine-1-carboxylate 
• 31970-04-4 1-carboxybenzyl-3-pyrrolidine 
• 932702-42-6 benzyl 3-(cyclopropylmethoxy) pyrrolidine-1-carboxylate 
• 25070-74-0 1-benzyloxycarbonylpyrrolidine 
• 1415573-78-2 benzyl (3R)-3-{[trans-4-(2-methoxy-2-oxoethyl)cyclohexyl]oxy}pyrrolidine-1-carboxylate 
• 1415573-76-0 benzyl (3R)-3-{[cis-4-(2-methoxy-2-oxoethyl)cyclohexyl]oxy}pyrrolidine-1-carboxylate 

Relevant academic research and scientific papers

Enantioselective reduction of heterocyclic ketones with low level of asymmetry using carrots

A whole spectrum of biocatalysts for asymmetric reduction of prochiral ketones is well known including the Daucus carota root. However, this type of reaction is still challenging when pro-chiral ketones present low level of asymmetry, like heterocyclic ketones. In this work, 4,5-dihydro-3(2H)-thiophenone (1), 2-methyltetrahydrofuran-3-one (2), N-Boc-3-pyrrolidinone (3), 1-Z-3-pyrrolidinone (4) and 1-benzyl-3-pyrrolidinone (5) were studied in order to obtain the respective enantioselective heterocyclic secondary alcohols. Except for 5, the corresponding alcohols were obtained in high values of conversion and with high selectivity. In order to circumvent the low isolated yield of the corresponding chiral alcohol from 2, we observed that the use of carrots in the absence of water is feasible. Addition of co-solvents was needed to the water-insoluble ketones 3 and 4. Comparatively, baker’s yeast was used for bio reductions of 1, 3 and 4. And in terms of conversion, selectivity and work-up, the use of carrots were a more efficient biocatalyst, as well as a viable method for obtaining 5-member heterocyclic secondary alcohols.

Design of wogonin-inspired selective cyclin-dependent kinase 9 (CDK9) inhibitors with potent in vitro and in vivo antitumor activity

Wogonin, a natural product isolated from the plant Scutellaria baicalensis, has been shown to be a potent and selective inhibitor of CDK9. With the purpose of investigating the activity and selectivity of this chemical scaffold, several series of wogonin derivatives were prepared and screened for CDK9 inhibition and cellular antiproliferative activity. Among these compounds, the drug-like compound 51 showed potent activity against CDK9 (IC50 = 19.9 nM) and MV4-11 cell growth (IC50 = 20 nM). In addition, compound 51 showed much improved physicochemical properties, such as water solubility, compared with the parent compound wogonin. The follow-up studies showed that the compound 51 is selective toward CDK9-overexpressing cancer cells over normal cells. Preliminary mechanism studies on the anticancer effect indicated that 51 inhibited the proliferation of MV4-11 cells via caspase-dependent apoptosis. In addition, highlighted compound 51 showed significant antitumor activity in mouse acute myeloid leukemia (AML) models without producing apparent toxic effects in vivo, which gave us a new tool for further investigation of CDK9-targeted inhibitor as a potential antitumor drug especially for AML.

RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AS WELL AS PREPARATION METHOD AND USE THEREOF

The present invention relates to a Rho-associated protein kinase inhibitor of Formula (I), a pharmaceutical composition comprising the same, a preparation method thereof, and use thereof for the prevention or treatment of a disease mediated by the Rho-associated protein kinase (ROCK).

SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1

The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): (Iar) wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Stereo-complementary bioreduction of saturated N-heterocyclic ketones

The asymmetric bioreduction of several saturated N-heterocyclic ketones is demonstrated in a stereo-complementary fashion using the ketoreductases READH and ChKRED20 for the production of (S)- and (R)-alcohols, respectively. The reaction accepts substrates with a five-, six- or seven-membered ring, and exhibits excellent stereoselectivity when using 2-propanol as both the ultimate reducing agent and cosolvent, achieve >99% ee in the majority of cases for both enantiomers.

PHENYL AMINO PYRIMIDINE BICYCLIC COMPOUNDS AND USES THEREOF

The present invention relates to phenyl amino pyrimidine bicyclic compounds formula (I) which are inhibitors of protein kinases including JAK kinases. In particular the compounds are active against JAK1, JAK2, JAK3 and TYK2 kinases. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases; and vascular diseases.

A library of conformationally restricted saturated heterocyclic sulfonyl chlorides

An approach to the synthesis of conformationally restricted saturated heterocyclic sulfonyl chlorides is described. Being guided by the principle of diversity-oriented conformational restriction, a mini-library of saturated heterocyclic sulfonyl chlorides

ALKYL-SUBSTITUTED 3' COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): wherein R1, R2, Ar, m and n are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

CONDENSED HETEROCYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I) wherein R1, A, B, D, E, G, Q, Ar, n, m, and p are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

ACYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): wherein R1, R2, R5, Q, G, Ar, m, and n are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.